Orencia (abatacept) is a protein pharmaceutical. Abatacept was first approved as Orencia on 2005-12-23. It is used to treat juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis. The pharmaceutical is active against T-lymphocyte activation antigen CD80 and T-lymphocyte activation antigen CD86.
|Indication||juvenile arthritis, psoriatic arthritis, rheumatoid arthritis|
|Drug Class||Receptor molecules, native or modified: T-cells|